Renin-angiotensin system inhibitors has been studied in 121 papers since 2016: 2 trials and 77 observational studies in people, 40 reviews; 85 in the past year. The newest story, Nov 7, 2026: “Renin-angiotensin system inhibitors linked to fewer deaths”.
Independent labs link renin-angiotensin system inhibitor use with lower mortality in human cohorts, including older patients with heart failure. Associations with muscle wasting and acute kidney injury differ across studies, while a human trial shows no clear cardiorespiratory fitness effect during high-intensity interval training in adults with metabolic syndrome. Papers name company funders and declare company ties.
61 findings in 38 papers from 2017 to 2026, 14 of them since June 2026
Independent labs found the same change in people. 30 independent labs in 16 countries.
“Chronic treatment with ACEi or ARBs does not appear to attenuate improvements in cardiometabolic health, BP, or CRF by 16 weeks of supervised HIIT in adults with MetS.”
Humans: replicated by independent labs. Cells: a single group. Worms or flies and mice: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
30 independent labs in 16 countries
4 findings against
Funders: Otsuka and others
10 of 54 findings with company ties
Human trial2
Humans76
In silico1
Studies in people
2 studies gave renin-angiotensin system inhibitors to people and measured what changed.
Renin-angiotensin system inhibitors were not clearly linked with major adverse cardiovascular events in humans (Hypertension with low renin; baseline treatment use) (HR 0.87, 95% CI 0.72–1.04).
“those with low renin did not benefit (HR=0.87, 95%CI 0.72-1.04).”
HumansHypertension with low renin; baseline treatment use
Renin-angiotensin system inhibitors were not clearly linked with vascular dementia in humans (compared with calcium channel blockers) (HR 0.74, 95% CI 0.50-1.11).
“but not vascular dementia (HR 0.74, 95% CI 0.50-1.11), compared with CCBs”
Renin-angiotensin system inhibitors showed no clear effect on cardiorespiratory fitness in humans during 16 weeks of HIIT in adults with metabolic syndrome.
“Chronic treatment with ACEi or ARBs does not appear to attenuate improvements in cardiometabolic health, BP, or CRF by 16 weeks of supervised HIIT in adults with MetS.”
Human trialduring 16 weeks of HIIT in adults with metabolic syndrome
Renin-angiotensin system inhibitors prevent cardiovascular and kidney end points in CKD.
“Both renin-angiotensin system inhibitors and sodium-glucose cotransporter 2 inhibitors are foundational therapies in CKD for the prevention of cardiovascular and kidney end points”
Renin-angiotensin system inhibitors are linked with lower abdominal aortic aneurysm growth rate in patients with diabetes mellitus / AAA surveillance (1.67 mm/year, 95% CI 1.52-1.83).
“and 1.67 mm/year, 95% CI 1.52-1.83, respectively”
Humansin patients with diabetes mellitus / AAA surveillance
Renin-angiotensin system inhibitors were not clearly linked with three-point major adverse cardiovascular events in humans (continued use (persistence)).
“Patients who maintained RASi had lower observed all-cause mortality and hospitalization rates, but no difference in incidence of 3P-MACE was found.”
What is renin-angiotensin system inhibitors linked with?
22
Studies link renin-angiotensin system inhibitors with 22 measures, most often mortality (11 studies), cardiovascular mortality (2) and Alzheimer's disease (2).
Mortality
↓downin humans11HR 0.47–0.93
11 studies
Renin-angiotensin system inhibitors are associated with mortality in humans (21.9% vs. 27.4%; HR 0.74, 95% CI 0.72–0.77).
“RASi use was associated with significantly lower all-cause mortality (21.9% vs. 27.4%; hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.72-0.77; p<0.001)”
HumansFollowing transcatheter aortic valve replacement; propensity score-matched comparison with non-usersMedian follow-up of 713 days56.9% malesn = 54,020
Renin-angiotensin system inhibitors are associated with mortality in humans (nonproteinuric chronic kidney disease) (3-year risk difference −3.39 percentage points (95% CI −4.71 to −2.07)).
“Initiation of RASIs may be associated with lower risks of all-cause and cardiovascular mortality in patients with nonproteinuric CKD.”
Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans after aortic valve replacement for severe aortic stenosis, propensity-matched (HR 0.68, 95% CI 0.59–0.78).
Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (full cohort, propensity score matched) (HR 0.93 (95% CI 0.91-0.95)).
“RASI use was associated with lower all-cause mortality (hazard ratio[HR] 0.93, 95% confidence interval[CI] 0.91-0.95, p< 0.001) in the full cohort”
Journal of clinical hypertension (Greenwich, Conn.)·
Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (very old patients (≥80 years), multivariate adjusted Cox regression) (HR 0.59 (0.42-0.83)).
“A survival-benefit was also observed with RASi-adjusted HR of 0.71 (0.50-1.01) and 0.59 (0.42-0.83) in non-VO and VO.”
Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (hospitalized with COVID-19) (OR 0.27, 95% CI 0.10, 0.75, p = 0.011).
“absence of baseline medication with RAAS inhibitors (OR 0.27, 95% CI 0.10, 0.75, p = 0.011)”
Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (elderly maintenance hemodialysis) (OR = 0.77, 95% CI: 0.58-0.90).
“taking angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker (OR = 0.77, 95% CI: 0.58-0.90) had a lower risk of mortality”
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia·
Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (positive control cohort) (HR 0.81 (95% CI 0.71-0.91)).
“In positive control patients aged ≤80 years (17 842 patients in the overall cohort, 2126 after matching), HR for all-cause mortality was 0.81 (0.71-0.91)”
Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (multivariate analysis in extremely elderly heart failure patients) (HR 0.470, P = 0.014).
“atrial fibrillation (HR 2.042, P = 0.015) and renin-angiotensin system inhibitors (HR 0.470, P = 0.014) were independent predictors for all-cause death in the extremely elderly group”
Renin-angiotensin system inhibitors are associated with cardiovascular mortality in humans (nonproteinuric chronic kidney disease) (3-year risk difference −1.46 percentage points (95% CI −2.57 to −0.52)).
“A significant association favoring RASIs initiation was also observed in terms of cardiovascular mortality, with a three-year risk difference of -1.46% (95%CI, -2.57% to -0.52%).”
Renin-angiotensin system inhibitors lower the risk of cardiovascular mortality in humans following TAVR for aortic stenosis (99.5% probability of P(OR < 0.8)).
“99.5% probability of a clinically relevant reduction in cardiovascular mortality”
Reviewfollowing TAVR for aortic stenosisn = 35,988
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·
Alzheimer's disease
↓downin humans2HR 0.59
2 studies
Renin-angiotensin system inhibitors are linked with a lower risk of Alzheimer's disease in humans (compared with calcium channel blockers) (HR 0.59, 95% CI 0.43-0.81).
“Initiation of RASIs was associated with a significantly lower risk of all-cause dementia (HR 0.68, 95% CI 0.55-0.84) and Alzheimer's disease (HR 0.59, 95% CI 0.43-0.81)”
Renin-angiotensin system inhibitors are associated with major adverse cardiovascular events in humans (Hypertension with high renin; baseline treatment use) (HR 0.76, 95% CI 0.63–0.92).
“patients with high-renin had the lowest risk (HR=0.76, 95%CI 0.63-0.92)”
HumansHypertension with high renin; baseline treatment use
Renin-angiotensin system inhibitors are associated with all-cause rehospitalization in humans (59.7% vs. 67.6%; HR 0.71, 95% CI 0.70–0.73; median time to first rehospitalization 349 vs. 83 days).
“RASi therapy was associated with significant reductions in mortality and rehospitalization with no meaningful increase in renal or cerebrovascular risk.”
HumansFollowing transcatheter aortic valve replacement; propensity score-matched comparison with non-usersMedian follow-up of 713 days56.9% malesn = 54,020
Renin-angiotensin system inhibitors are associated with composite kidney outcome in humans (nonproteinuric chronic kidney disease) (3-year risk difference −0.88 percentage points (95% CI −2.42 to 1.40); not statistically significant).
“A similar trend of association was observed for composite kidney outcomes, though the three-year cumulative risk difference between groups did not reach statistical significance”
Renin-angiotensin system inhibitors are associated with NT-proBNP in humans (prescription at discharge after aortic valve replacement, reflecting disease stage) (1,238 vs 971 pg/ml).
“Patients receiving RASi (LVEF <50%: 17.2% vs. 10.1%; NT-proBNP: 1,238 pg/ml vs. 971 pg/ml)”
Humansprescription at discharge after aortic valve replacement, reflecting disease stage
Heart failure hospitalisation or cardiovascular mortality
↓downin humans1HR 0.93
1 study
Renin-angiotensin system inhibitors are linked with a lower risk of heart failure hospitalisation or cardiovascular mortality in humans after surgical or transcatheter aortic valve replacement, weighted Cox model (HR 0.93 (95% CI 0.89–0.98)).
“RAASi (HR: 0.93 95% CI:0.89-0.98)”
Humansafter surgical or transcatheter aortic valve replacement, weighted Cox model
Renin-angiotensin system inhibitors are associated with all-cause death or heart-failure hospitalization in humans (Dialysis-dependent patients hospitalized for worsening heart failure).
“Drug-specific analyses identified RASis intensification as the strongest contributor to the improved prognosis.”
HumansDialysis-dependent patients hospitalized for worsening heart failure
Studies name major neurocognitive disorders as acting on renin-angiotensin system inhibitors.
Major neurocognitive disorders
↓downin humans1
1 study
Major neurocognitive disorders are linked with lower renin-angiotensin system inhibitors in individuals diagnosed with heart failure.
“We found a lower prevalence of filled prescriptions of renin-angiotensin system (RAS) inhibitors, β-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs) among patients with major NCD.”
Reviews describe longer rodent lifespan; human studies from independent labs link renin-angiotensin system inhibitors with lower mortality, including in older hypertensive patients. Use is linked with less muscle wasting in heart-failure patients with diabetes, but not clearly linked without diabetes. A heart-failure analysis finds no clear mortality link; four of 22 papers declare company ties.
In adults with hypertension, one human study shows renin-angiotensin system inhibitors lower the risk of dementia and Alzheimer's disease, but not vascular dementia. Reviews also link them to a lower risk of heart failure across high-risk populations.
After catheter-based aortic valve replacement, deaths occurred in 21.9% of people prescribed the drugs versus 27.4% of non-users over a median follow-up of 713 days.After catheter-based aortic valve replacement, deaths occurred in 21.9% of people prescribed the drugs versus 27.4% of non-users over a median follow-up of 713 days.